Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
August 13, 2020
Earnings Call Speaker Segments
Jennifer Good
executiveThank you, Grace. Hello, everyone, and good afternoon. We're glad you could join us for this first earnings call. Since we've been delivering on our business plan, we believe now is the right moment to begin providing updates on a more consistent basis. The second quarter kept us occupied, and that pace has carried into the summer. While that period was underway, we were adjusting to how COVID affected our staff and our clinical trials—first by halting all activity, then by evaluating where things stood, and finally by getting things going once more. Starting in May, we managed to get sites open again so they could screen and enroll participants in our primary study of pruritus in prurigo nodularis, or PN. In July, we also shared news that a prespecified sample size reestimation analysis for the PN trial had produced a favorable result, and I'll go into further detail on that shortly. In addition, we announced today a $14 million term loan that strengthens our balance sheet and pushes our cash runway out to the first half of 2022; Chris will cover that in greater detail when he speaks. Last, we had the Trevi team return to the office in July under a hybrid arrangement. The shift to working from home went so smoothly that I've been quite happy about it, and I give the team credit for putting in the effort to make it work. Still, returning to something closer to normal has felt good, and so has the benefit a small company gets from synergy when people see each other face to face. Let me pause briefly and restate our growth strategy for everyone. Trevi is working on nalbuphine ER, also called Haduvio, to investigate what treatment effect it might have across a range of serious neurologically mediated conditions. This drug has pharmacological activity at 2 receptors—acting as a mu antagonist and likewise as a kappa agonist. These receptors show up in a lot of places in the body, including the skin, the lungs, the spinal cord, and certain brain areas like the brainstem. We've zeroed in on pruritus, cough, and movement disorders as the clinical conditions we want to target therapeutically, because the science tells us that what happens at the mu receptor and the kappa receptor really matters for these conditions. Our lead clinical development indication is severe pruritus in prurigo nodularis — a significant and debilitating skin condition characterized by papules and nodules, plus itching that is severe and never lets up. To date, nothing has been approved to treat this indication. Prurigo nodularis is a chronic disease, and repeated scratching causes the papules and nodules to spread and keep getting worse. We estimate roughly 250,000 PN patients live in the U.S., with another 430,000 across the rest of the world. Biologics are also in development for pruritus in PN, yet we are the sole oral drug being developed for this condition; our view is that biologics and oral therapeutics alike will each have significant, complementary roles in managing this chronic disease. Looking at the longer term, an oral option will probably matter a great deal for patients. Right now, we're running what we refer to as our PRISM trial — a Phase IIb/III study involving these subjects who have prurigo nodularis. Recruitment is happening across both the U.S. and Europe, and as of today, over 60 sites are up and running. The main endpoint is a responder analysis looking at how much itch intensity drops, measured through the Worst Itch Numerical Rating Scale following 12 weeks of blinded fixed dosing. Back in July, the company hit a significant milestone for this program when we reported that a prespecified sample size reestimation analysis, or SSRE, had been completed with a positive outcome in this trial. That analysis relied on a prespecified interim conditional power and was carried out by an external unblinded statistician once roughly 45% of the initially targeted patient number became evaluable for the primary study end point. After the SSRE analysis came in, the independent data monitoring committee recommended continuing the PRISM trial and expanding enrollment to 360 subjects so that statistical power for the primary end point would be maintained. Because we stayed blinded to the underlying results, we don't know what drove that sample size increase. As a reminder, though, moving up to 360 subjects was inside the range the company had already specified in advance, reflecting a variety of powering assumptions along with the Phase II results. At this interim point, we were pleased to see the drug appearing to show efficacy within a range that, when the study was designed, we had judged clinically relevant. To handle a potential increase in the number of subjects, our clinical operations team has been preparing to open additional sites should the need arise. Our view is that we already have enough locations either active or being brought online to complete this trial within the timelines we've set. As of now, the trial has approximately 155 subjects randomized. In May, restrictions on screening and enrollment were removed at all our sites. Currently, roughly 80% of our locations have resumed screening patients after the pause imposed by COVID restrictions. Enrollment has gotten off to a solid start at these sites, and June along with July represent the two strongest back-to-back months of enrollment we've seen so far. Also, the typical dip in enrollment we'd expect in August during clinical development isn't happening. There's more good news for the study: more than 95% of subjects who got to week 14 decided to enter the open-label extension part. Given how enrollment has picked up since pandemic restrictions eased, plus the larger sample size for the trial, we think we can finish enrolling in the third quarter of 2021, with top line data in the fourth quarter of 2021. We're pleased with how this trial is going and will keep pushing to hit these important milestones. Moving on to the second clinical program in Phase II, which addresses cough associated with idiopathic pulmonary fibrosis, also known as IPF. This disease is serious as well, marked by the formation of scar tissue within the lungs. Among the primary symptoms that prove most debilitating for those with this condition is chronic coughing, which affects an estimated 70% to 85% of patients. There are currently no therapies approved to treat it. Our ongoing trial is a Phase II double-blind crossover study, and each 3-week treatment period is followed by a 14-day washout. The main end point being assessed is the mean percent change from baseline in daytime cough frequency. To capture daytime cough frequency, a digital cough monitor is used, comparing the treatment arm against the placebo arm. This trial is taking place in the U.K., and since this patient group carries high risk for COVID because of their lung impairment, we voluntarily halted all screening and enrollment activities; we've utilized this period to concentrate on amending study procedures that will boost our capacity to effectively enroll in this patient population amid COVID limitations and intend to put in place a protocol amendment permitting fewer hospital visits. We feel we're well positioned as this study gets ready to resume, and already 4 of our 11 sites have signaled they are prepared to restart the study. We anticipate being able to begin screening patients once more later this year. Beyond those, we're running several additional initiatives that haven't advanced as far yet. Even so, we chose to put our itching and cough efforts first, since doing so lets us make the most of how we run development and the resources the company has. That leads nicely into handing things over to Trevi's Chief Financial Officer, Chris Seiter, who will walk you through the financial picture. Chris?
Chris Seiter
executiveThanks, Jennifer. Just a note that you can find the complete financial results for Q2 2020 in our 10-Q, which we filed with the SEC today after market close. For Q2 2020, we reported a net loss of $7.4 million, versus a net loss of $7.3 million in the same quarter of 2019. R&D expenses came in at $4.9 million during Q2 2020, compared to $5.5 million in the same period of 2019. That decrease was mainly driven by lower activity in our Phase II trial in chronic cough in patients with IPF, because enrollment and treatment of patients were halted due to the COVID-19 pandemic. G&A expenses were $2.5 million during Q2 2020, compared to $1.9 million in the same period of 2019. That increase was primarily attributable to higher stock-based compensation expenses and higher expenses related to being a public company. As of June 30, 2020, our cash and cash equivalents totaled $44.2 million, compared to $57.3 million as of December 31, 2019. We've put funding strategies in place using both debt and equity to extend our cash runway. During Q2, we filed an at-the-market, or ATM, prospectus. After the end of Q2, we sold approximately $2.2 million of our common stock through the ATM facility. Also, earlier today, we entered into a $14 million term loan facility with Silicon Valley Bank. The term loan calls for monthly interest-only payments through February 28, 2022, then monthly payments of principal and interest until February 1, 2024. Interest on the term loan initially accrues at a per annum rate of 4.25%. The proceeds from the ATM and the nondilutive term loan strengthen our cash position and will extend our cash runway into the first half of 2022, past the anticipated top line results from the PRISM trial, which are expected in Q4 2021. That's everything for our prepared remarks. Now I'll hand the call back to the operator for Q&A.
Gary Nachman
analystNow that PRISM has been reestimated and increased to 360 — the ceiling that had been set in advance — could you actually exceed that figure if you wanted extra reassurance? And when we're at 360, does statistical power still hold at 90%? Could you put a number on that for us, Jen?
Jennifer Good
executiveYeah. Thanks, Gary. That's correct — the original was powered at 90%. The actual calculations aren't something we see, but that was the study's underlying premise. Regarding exceeding the sample size, it works much like any trial: when patients are already in the pipeline, you can essentially allow them to complete. Strictly speaking, though, the experiment you're conducting rests on a given sample size. So my sense is that's the figure we'll aim for; then again, quite often these things wind up going somewhat beyond on patients, simply because of those already in the queue.
Gary Nachman
analystAll right. Then, what's your approach when it comes to handling patients who stop treatment? You've brought this up before. Did the pandemic make it harder to give them the right information? And could that possibly explain why the dose was increased all the way to the maximum? Or can we not really know?
Jennifer Good
executiveLet me address your final question first, so it doesn't slip my mind. We can't see what caused it, though that's definitely a possibility, since when discontinuations are basically treated as failures of treatment, pinning down precisely what those are becomes difficult; so that might have contributed. Site-to-site variation could also be at play. Many different elements feed into that math, so honestly I don't have a clear read on what it could be. Regarding our handling of it, we've invested heavily in this trial — not just site training, but we also have solid materials aimed at patients. We regularly check in with our 60 sites to confirm they're focused on this and dealing with patients the right way. So nothing concerning or troubling has shown up. It's essentially routine. I'd say that amid the pandemic — somewhat opposite to your suggestion and also to my own concerns — the rate of discontinuations didn't rise. In fact, I believe they actually fell somewhat, since patients were at home. They weren't juggling work and rushing about, I think. There was strong focus. We had, I believe, just a single visit missed over that period. Nobody in the blinded part of the study was lost because of COVID. So early on, we paused some activities and implemented everything everyone was doing regarding delivering drug to patients, worrying about sites, and waiving visits — and it turned out we didn't need that for PN. IPF was somewhat different, as I said, given what those patients are like; but for PN, things actually stayed together quite well.
Gary Nachman
analystGary, thanks for that — and one more quick item before we wrap up. On the IPF study, my understanding is that you're changing the protocol so that hospital visits happen less often. And I believe you mentioned that 4 of the 11 sites are already prepared to begin. That said, considering the pandemic, if the U.K. turns out to be a tough place to run this because of how cases are unfolding there, would it make sense to look at countries beyond it? Jennifer, over to you.
Jennifer Good
executiveGreat question, Gary — perhaps you ought to go head up a small drug development company someday. The answer is yes, we're looking into that, since we already have trials running in Germany, which happens to be an excellent location for this kind of work, along with Austria and France. For precisely the reasons you just gave, we're actually evaluating whether to bring in an additional country. It comes down more to reducing risk and ensuring we aren't chained to whatever conditions exist in a single nation while the pandemic continues. So all of those possibilities are ones we're currently considering.
Ami Fadia
analystFirst off, regarding the PN study — enrollment looked quite robust in June and July. Could there have been some kind of bolus of patients tied to the pandemic? And how should we think about the pace at which you can bring patients in over the next several months? Are new sites being opened that might keep funneling additional patients into the trial?
Jennifer Good
executiveYeah, absolutely. The bolus question is a fair one. My sense is that sites stayed productive throughout what turned out to be a fairly short pause. Even so, I believe they were productive in terms of reaching out to patients — something they likely would have done eventually, but they used that period to get some people lined up. What's nice, and encouraging to me, is that it carried on through June and July, and now we're seeing that continue into August. I think it's really more about 2 things. First, we had a competitor in this space, enrolling in the same trial, that basically came out with negative results during the whole COVID transition. That helps, I think, because it took them out of the running for the same patients. The second thing is exactly what you mentioned — we actually did quite well during this window at bringing new sites on board. And people have gotten very creative about conducting virtual SIVs and getting sites up and running. So we'll keep adding some new sites into the mix, since I think bringing in some of these fresh patients was a good thing. But I think we're just about there in terms of how many sites we need to enroll in this. So I do think there was a bit of a bolus in June. June was a nice month, but it stayed strong through July and August; so at the run rates we're at, we're in a good position with the number of sites we have.
Ami Fadia
analystUnderstood. Regarding the open extension portion of the trial, could you share some detail on the number of patients who decided to participate and the duration of their follow-up? Also, any anecdotal observations would be helpful.
Jennifer Good
executiveOf course. As I noted in my remarks, more than 95% of patients made the choice to enter the open-label extension. That adds 38 weeks. So after completing the initial 14 weeks, someone could receive treatment for as long as a year. Some individuals dropped out — or halted participation at various junctures for various reasons. Their itch diminishes to a low level. Life gets in the way. Even so, a good number of patients have gone the entire distance through that period. Consequently, we still have many patients enrolled in that study. I consistently view it as a positive indicator when individuals decide to keep going into the open-label extension. As for anecdotes, naturally, it's the same sort of thing you'd typically hear about in trials. We're receiving plenty of favorable reports regarding skin recovery and itch score improvements and similar matters. As I mentioned, close to 20 patients have reached the full year; so many positive, encouraging developments; in fact, we're capturing photographs at a number of the sites. We haven't begun reviewing those yet, since that represents a genuine sort of ultimate prize here — when you can get the skin to heal — but we're hearing a great deal of encouraging information coming out of the open-label study.
Ami Fadia
analystCould you verify something for me — did you not have visibility into the overall trial's discontinuation rate?
Jennifer Good
executiveThat's not right. The overall discontinuation rate is something we're aware of, yet we don't tend to discuss it in detail, simply because I lack visibility on whether patients received the drug or the placebo. So the overall discontinuation rate doesn't fall outside our prior assumptions. The issue is that parsing it is extremely difficult, since you've got patients dropping out at every point along the way, roughly 12 weeks in, because of itching. Whether they're on drug or placebo, I have no clue. That makes it genuinely tough to parse what it signifies from a drug standpoint. It's a matter, I'd say, that the team is handling well.
Ami Fadia
analystUnderstood. One more thing regarding IPF — approximately what kind of timeline could there be before the study reads out? I realize it's still fairly early in the process, but what sort of rough timeline would you provide?
Jennifer Good
executiveRight. Ami, as you're aware, we've put guidance out there of by year-end, though because of COVID, we walked that back. And I believe until we — 44 completers are needed. I believe until we get that going with our U.K. sites and, regarding Gary's question, whether any other territories will be opened, we were reluctant to put a date out there. So I believe, hopefully, by the next quarter, we'll have greater visibility on that once sites actually get going. So I don't want to lay out any dates yet simply because when we do that, I want to be sure it's something we're confident we can hit.
Annabel Samimy
analystI'm not sure I have any questions remaining, though naturally I do. Let me return to the topic of upsizing briefly. There's something you mentioned that I'd like clarified. You've reached the highest permitted threshold for upsizing. So my first question, I suppose, is how are we meant to interpret that, given it was the ceiling that's allowed? Then the second thing I'd like to dig into is the timing — you stated that your powering was preserved, yet it sounded like you were hinting there's still some flexibility regarding bringing in additional patients in the event that you lose some? I'd just like to grasp precisely what you were getting at there.
Jennifer Good
executiveAll right. No, regarding the second part, to clarify, our power is indeed maintained. And beyond the usual situation in a trial, we truly don't have flexibility — for instance, if you've got, let's say, 10 patients in the queue when you reach your 360, typically you'd allow them to complete. That's the reason trials never quite land exactly on the figure they were aiming for. But no, we aren't expecting to require any flexibility in an attempt to generate a small efficacy read. So 360 is our N; that's our target, and we'll finish up in and around that figure. Your first question concerned, ah, how to interpret that upper limit; it's difficult to...
Annabel Samimy
analystYeah. At times, you know, you increase the dose — it could be by 20% or 30%. Here it went completely to the ceiling, so that's what made me wonder.
Jennifer Good
executiveRight. Annabel, the way I understand it, there's a little bit of magic happening behind the curtain, since none of those calculations are visible to you, and no single figure exists. Instead, you have these bands of figures. And my sense is that whenever you land within one of those bands, you wind up at its top. The one thing I can infer is that at 360, the picture would have resembled what our Phase II results show. That's the reason we chose that figure. So we had this band, and we'd already decided we would aim to enroll at its bottom, then verify again at the midpoint. And should we need to climb toward what our Phase II results showed, we could proceed in a stepwise manner. That's basically what took place.
Annabel Samimy
analystOkay. Then, regarding how these patients are tracked, I'd like to dig deeper into what it takes to monitor them, so it's encouraging that enrollment is underway. Could you describe the way they're being watched over throughout this COVID period? Given that COVID is sort of spreading across the nation and creating chaos, even beyond only the Northeast area, so what has your approach been with these patients? Also, how frequently must they physically show up for visits? Or is everything being done virtually now?
Jennifer Good
executiveNo, I'd say — it's somewhat, quite a bit actually, to my surprise, every one of these visits has continued with people actually arriving at the office; for studies already running, these derm patients, they — especially the PN patients, usually don't have other underlying medical conditions; and as a result they could keep going through their visits; and so in the end that wasn't an issue. When it comes to the monitoring visits, that too was something that got paused but has begun to reopen in various countries. I'm aware that in Germany, they're monitoring in person; they are doing remote monitoring, I know. So every site differs somewhat. Certain sites are permitting monitors on-site to go ahead and monitor. At other sites, they're doing whatever they can remotely, and afterward they'll need to go in and verify some of the patient-based data when they're in-house, but the monitoring is progressing.
Annabel Samimy
analystAlright, so for my final question — I have to admit, it caught me off guard that you're projecting enrollment to wrap up in Q3 of '21. Since the competing program is no longer in the picture, and enrollment moved quite quickly over the recent months, would you say that represents the most cautious estimate? Or might things accelerate and allow you to finish sooner?
Jennifer Good
executiveNaturally, whenever possible, we aim to outperform our targets. In our view, this is a sensible projection. It isn't an overly ambitious one. Personally, I would be delighted if we could surpass it. That said, these patients present real difficulties. They represent the most severe cases among PN patients. We're also aware of additional rival trials involving biologics. So I'd call it a grounded timeline. Over the coming months, as we observe the degree to which COVID keeps disrupting trials, we're hoping to gain somewhat clearer visibility into that.
Annabel Samimy
analystAll right, and on that same topic, I have one additional question, apologies. Do the remaining biologics address an underlying condition that ultimately shows up as prurigo nodularis? Or do they truly aim at PN directly?
Jennifer Good
executiveCorrect. No, their focus is pruritus in prurigo nodularis, the same as ours. Two studies are underway for Dupixent, and Galderma has stated they will launch trials. Kiniksa, meanwhile, isn't really moving forward, though they have performed some work in this area. So it's a comparable field. Still, in my view, most of these biologics are simply behaving the way biologics typically do. I believe an oral option is greatly needed here. That said, we haven't encountered many of them at the clinical sites, but it's worth keeping an eye on.
Serge Belanger
analystOnly a few from my side. I suppose the initial one would be whether there's any variation in the way PN patients in the U.S. versus Europe receive treatment, and do you anticipate they might respond differently to nalbuphine during the study?
Jennifer Good
executiveNo. So, Serge, my view is that patients in the U.S. and Western Europe share comparable definitions. Across those regions, the KOL community is more or less aligned. We've seen some solid support for that, not just in our Phase II data, where no disparity showed up, but Menlo has recently shared findings from both a U.S. trial and a European one. The placebo responses looked highly alike, and the drug's impact was likewise very alike in each. Thus, in their studies — each involving roughly 300 patients, around 300 per study — we observed no distinctions between the 2 patient groups. So no differences are appearing, and I believe that gave us additional proof that we ought to be able to conduct the work across both territories.
Serge Belanger
analystAll right. Then regarding the IPF cough trial, my understanding is that at the start, the plan was to enroll 56 patients and get roughly 40 responders. Does that remain the goal, or would you consider enrolling fewer people so the results could be reported sooner?
Jennifer Good
executiveYeah. That's a fair question. All of you are reasoning along the same lines we are. We still aim for 56, with 44 completing. We're looking into several options. First, we wanted to determine how many U.K. sites we could activate and on what timeline. Something favorable has happened that I didn't bring up earlier: many of the people running IPF trials that had strong enrollment saw a large portion of those patients withdraw, which damaged their studies. As a result, they've left the area; what had been a highly competitive area in IPF, and we had one competitor in IPF cough, has now emptied out. So these sites are genuinely eager to get new — to restart studies. So I want to get a sense of that, and see how the COVID situation unfolds. We'll go after an additional country, which we would put ahead of running a somewhat smaller study. That said, this is truly a Phase II proof-of-concept study. So if it seems like it will stretch out and consume too much time, we might at some stage set a cutoff and check whether the drug looks like it's working; so all of those are possibilities we're considering. But right now, the team prefers to conduct it at the original sample size, since we believe that yields more interpretable data.
Jennifer Good
executiveChris and I want to express our appreciation to each of you for joining today's call. Our thanks also go out to the folks at Trevi, the investigators running our studies, and every patient still taking part in our clinical trials throughout this extremely difficult period; we're eager for ongoing advances and to bring you fresh updates before long. Have a great remainder of your summer, and please stay well. Thanks so much.
Operator
operatorEveryone, that wraps up the call for today. We appreciate each of you for being here. At this point, you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.